Business Context and Reporting Period
This Form 8-K is a current report filed by Madrigal Pharmaceuticals, Inc. (MDGL) on April 22, 2026. The filing addresses corporate governance changes regarding the Board of Directors ahead of the Company's 2026 Annual Meeting of Stockholders scheduled for June 17, 2026.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on director reclassification and does not contain financial performance data.
Material Changes
Effective April 22, 2026, the Board reclassified two directors to achieve a more equal apportionment of membership among the three director classes:
- Julian C. Baker: Reclassified from Class III (term expiring 2028) to Class I (term expiring 2026).
- Daniel J. Brennan: Reclassified from Class II (term expiring 2027) to Class I (term expiring 2026).
Both directors resigned from their previous classes and were simultaneously reappointed to Class I. Their service on the Board is deemed uninterrupted, and there were no changes to their committee assignments.
Guidance, Outlook, and Management Commentary
The filing notes that Mr. Baker, Mr. Brennan, and James Daly have been nominated to stand for re-election at the 2026 Annual Meeting, as disclosed in the Definitive Proxy Statement filed on April 28, 2026. No financial guidance, risk factors, or unusual items are discussed in this specific report.
Investor Verification Checklist
- Verify the full composition of the Board of Directors and the specific terms of the three director classes in the upcoming Definitive Proxy Statement.
- Confirm the voting procedures for the re-election of Julian C. Baker, Daniel J. Brennan, and James Daly at the June 17, 2026 Annual Meeting.
- Review the Definitive Proxy Statement filed on April 28, 2026, for detailed biographical information and any potential conflicts of interest regarding the reclassified directors.